Tuesday January 20 2026 at 5:30 pm (CET)
Aromatase inhibitors (AIs) are used sequentially to treat ER+ breast cancer, yet resistance limits benefit. This session integrates WES from 11 patients across three treatment timepoints (Neoletexe trial) with single-cell DNA sequencing validation to reconstruct subclonal architectures. We’ll connect rising cancer cell fraction trajectories with reduced response, contrast exemestane- vs. letrozole-resistant clones, and highlight clinically actionable alterations—spanning PI3K/AKT/mTOR, CDK4/6, DNA repair, and immune checkpoint pathways.
Speakers:
Dr. Denise O’Mahony
Post-doctoral Researcher, Oslo University Hospital
Dr. O’Mahony is a geneticist whose PhD at the Cyprus Institute of Neurology and Genetics focused on breast cancer genetic epidemiology, including interpretation of BRCA1/2 VUS, novel methods for large case–control datasets, and Bayesian fine-mapping. Her postdoctoral work explores subclonal tumor reconstruction during aromatase inhibition, polygenic modeling for early risk and outcomes, and AI-driven pipelines for variant impact prediction. She is an active member of BCAC and serves on the International Genetic Epidemiology Society committee.
Professor, Director of Research and Head of the Division of Research and Development, Oslo University Hospital
Thursday November 20 2025 at 5.00 pm (CEST)
Acute myeloid leukemia (AML) remains one of the most heterogeneous hematologic malignancies, both at the genetic and phenotypic levels. Despite initial responses to therapy, relapse is frequent and largely driven by a rare population of leukemic stem cells (LSC), which persist in up to 70–80% of AML cases and act as a reservoir for disease propagation and resistance. Traditional bulk approaches have provided key insights into AML biology but inherently obscure the cellular diversity that shapes disease evolution and therapeutic escape.
Here, we leveraged single-cell proteogenomics to dissect the heterogeneity of LSC at unprecedented resolution. By combining high-dimensional genotyping with a custom-designed antibody panel, we were able to simultaneously capture mutational landscapes and phenotypic profiles of stem and progenitor compartments. This approach uncovered unexpected subclonal architectures, revealed co-existing immunophenotypic states within genetically defined clones, and highlighted rare but clinically relevant LSC subsets that would have been invisible using conventional methods.
Our work illustrates how single-cell proteogenomics can bridge the gap between genotype and phenotype in AML, offering a powerful framework to better understand LSC biology, monitor minimal residual disease, and ultimately inform precision therapeutic strategies.
Speaker:
Benjamin Podvin, PharmD, PhD student, is a medical biologist specialized in hematology at Lille University Hospital, France. His research focuses on single-cell multi-omics and translational applications in hematologic malignancies, with a particular interest in acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma. He has been involved in the development of innovative single-cell proteogenomic approaches to study leukemic stem cell heterogeneity and resistance mechanisms. Alongside his clinical and research activities, he also teaches hematology and molecular diagnostics to medical students.
Wednesday November 12 2025 at 5.00 pm (CEST)
See how single-cell DNA + DNA methylation + surface protein profiling with scTAM-seq (on Tapestri) dissects treatment response in MDS/AML using sequential patient bone-marrow samples collected during targeted therapy.
Speaker:
Tuesday September 23 2025 at 5.00 pm (CEST)
Watch here
Clonal hematopoiesis (CH) has emerged as a critical factor in cancer biology, yet its role in diffuse large B-cell lymphoma (DLBCL) remains unclear. Does CH directly drive lymphoma initiation, or does it subtly shape the tumor-microenvironment?
In this webinar, Dr. Deborah Piffaretti will present breaking DLBCL data insights from clinical trials and preclinical models that combine advanced single-cell multiomic sequencing with functional studies. The results challenge existing assumptions, showing that CH, while prevalent, may have limited impact on DLBCL pathogenesis.
This session will not only provide clarity on the biological significance of CH in lymphoma but also highlight how single-cell multiomic methods can dissect complex tumor-microenvironment interactions.
Learn more about VisionSort applications in stem cell R&D and regenerative medicine.
Highlights include applications in induced pluripotent stem cells (iPSC), human mesenchymal stem cells (hMSC), and progenitor cells.
Combining gentle microfluidics based sorting that maintains stem cell viability and differentiation potential with sensitive, label-free isolation of specific cell phenotypes, VisionSort is uniquely positioned to address fundamental challenges in stem cell R&D and regenerative medicine.
Thursday, March 20, 2025
11:30 am CET
Registration
Learn more about viral applications and how to optimize.
Topics:
Wednesday, March 12, 2025
3 pm CET
Registration – Zoom
Learn how the VisionSort Platform combines traditional fluorescence flow cytometry with high-dimensional morphological profiling and AI to enable label-free cell sorting and unbiased single cell profiling.
Interested in morphological profiling but can´t attend the webinar?
Contact one of our Technical Specialists to set up and introductory meeting to learn more.
Monday, Sept 16th, 2024
10:30 – 15.00
Registration – Zoom
Join us for a special seminar where we explore how single-cell DNA multiomics help unveiling cellular complexity. Quantitative characterization of genotype and phenotype at the single-cell level reveals clonal phylogeny and selection at higher resolution, ultimately improving personalized therapeutic selection. By identifying SNVs, CNVs, and surface protein changes and revealing co-occurrence and zygosity of mutations in single cells, Tapestri enables comprehensive insights into disease progression, development of therapy resistance, and MRD. Our invited speakers will present data from different areas of research like acute myeloid leukemia (AML), single-cell MRD in AML, functional phenotyping of genomic variants using multiomic scDNA-scRNA-seq, single-cell DNA seq assay for reconstructing the clonal evolution of tumors from FFPE samples, targeted single-cell DNA methylation (scTAM-seq), single-cell Multiple Myeloma multiomics and genome editing.
Tuesday, Sept 10th, 2024
13.00 – 15.00h
Rudbecklaboratoriet, Waldenströmsalen
Join us to discuss news in clonal single cell multiomics analysis with Tapestri. The meeting is arranged in collaboration with the FIMM and will cover:
Enhanced flexibility and cost savings with multiplex capability
Applications: scMRD in AML, sc multiomics for Multiple Myeloma, DNA methylation, genome-wide CNV analysis, gene editing assessment
Open forum discussion
Tuesday, Sept 3rd, 2024
11.00 – 12:30h
FIMM 3rd floor lunch area, Biomedicum 2U
Join us to discuss news in clonal single cell multiomics analysis with Tapestri. The meeting is arranged in collaboration with the FIMM and will cover:
Enhanced flexibility and cost savings with multiplex capability
Applications: scMRD in AML, sc multiomics for Multiple Myeloma, DNA methylation, genome-wide CNV analysis, gene editing assessment
Open forum discussion
Join us to discuss news in clonal single cell multiomics analysis with Tapestri. The meeting is arranged in collaboration with the FIMM and will cover:
Enhanced flexibility and cost savings with multiplex capability
Applications: scMRD in AML, sc multiomics for Multiple Myeloma, DNA methylation, genome-wide CNV analysis, gene editing assessment
Open forum discussion
Thursday June 6 2024, 5:00 pm (CET)
Despite the richer insights that single-cell multi-omics can offer over conventional techniques such as PCR and bulk next-generation sequencing, including characterizing the clonality of heterogeneous cancer cells and changes driving therapy resistance or assessing genome editing outcomes, the costs for sample analysis can be a barrier to adoption for many labs.
To help address this, Mission Bio has recently launched new sample multiplexing features that allow the pooling of multiple samples into a single run on the Tapestri Platform, improving the throughput and productivity, and thereby reducing the per-sample costs for single-cell DNA and protein multi-omic analysis by up to 60%*.
In this educational webinar, we’ll discuss two novel multiplexing approaches available on Tapestri, Antibody Hashing and Genotype Multiplexing. We’ll explore how they enable increased efficiency and versatility while maintaining the same robust performance metrics such as sensitivity and specificity. We’ll also share real-world case studies from labs that are applying multiplexing approaches in disease modeling, CRISPR-editing, and hemato-oncology applications.
Wednesday May 29 2024, 4:00 pm (CET)
Infant and adult MLL1/KMT2A-rearranged (MLLr) leukemia represents a disease with a dismal prognosis. Here, we characterized early proteomic events of MLL::ENL-mediated transformation in fetal and adult blood progenitors and reveal that whereas adult pre-leukemic cells are mainly characterized by retained myeloid features and downregulation of ribosomal and metabolic proteins, expression of MLL::ENL in fetal lymphomyeloid multipotent progenitors (LMPPs) leads to enrichment of translation-associated and histone deacetylases signaling proteins, and decreased expression of inflammation and myeloid differentiation proteins. Integrating the proteome of pre-leukemic cells with their secretome and the proteomic composition of the extracellular environment of normal progenitors highlights ligand-receptor interactions with differential regulation upon initiation of fetal- and adult-origin leukemia. We show that these interactions have implications for human MLLr leukemia cells’ ability to communicate with their environment through granule proteins. Our study has uncovered opportunities for targeting ontogeny-specific proteomic vulnerabilities in in utero-initiated and adult-onset MLLr leukemia.
Wednesday April 24 2024, 4:00 pm (CET)
Improving coverage, robustness and sensitivity is crucial for routine phosphoproteomics analysis by single-shot liquid chromatography tandem mass spectrometry (LC-MS/MS) from minimal peptide inputs. The presentation focuses on our systematic optimization of key experimental parameters for automated on-beads phosphoproteomics sample preparation with focus on low input samples, pinpointing critical variables influencing the resulting phosphoproteome. Furthermore, we evaluated how sequential enrichment can boost phosphoproteome coverage and show that pooling fractions into a single LC-MS/MS analysis can increase the depth. The presentation also includes an alternative phosphopeptide enrichment strategy based on stepwise addition of beads thereby boosting phosphoproteome coverage. Our optimized phosphoproteomics pipeline can be translated to the newest generation of mass spectrometers, such as the Orbitrap Astral, increasing the phosphopeptide coverage by 2-fold, allowing for deep phosphoproteomics analysis without the need to scale up the starting cell amounts.
Wednesday April 3 2024, 4:00 pm (CET)
Proteins are the primary targets of almost all small molecule drugs. Nonetheless, even drugs designed with high specificity may interact with multiple proteins that are not initially targeted. Discovering these potential interactions is crucial for the development and repurposing of drugs. Current state-of-the-art proteomics methodologies enable screening of thousands of proteins against a limited number of drug molecules. Here we report the development of a label-free quantitative proteomics approach that enables proteome-wide screening of small organic molecules in a scalable, reproducible, and rapid manner by streamlining the proteome integral solubility alteration (PISA) assay.
Tuesday Oct 10 2023 3 pm (CEST)
Quantitative determination of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in human serum and plasma
This webinar will focus on Pre-Eclampsia and improving clinical pathways with PkGF / sFlt-1, including a brief introduction of Pre-eclampsia and insight into the inclusion of biomarkers sFlt-1 & PlGF.
We will be joined by Professor Tim James, Laboratory Manager and Head BioMedical Scientist in Clinical BioChemistry at Oxford University Hospitals.
Professor James will be discussing his own experiences from Oxford to provide insight, advice and guidance to highlight the clinical significance and favourable outcomes of sFlt-1 & PlGF.
Professor Tim James is Laboratory Manager and Head Biomedical Scientist in Clinical Biochemistry at Oxford University Hospitals NHS Foundation Trust, a post he has held for over 20 years.
Within this role he manages three laboratory sites including a large teaching hospital service. Working with clinical departments to better understand testing and to ensure optimal utilisation is a key aim of the service. He has worked with many clinical teams to evaluate current testing and where possible introduce new diagnostics where there are clear benefits for patients.
He has published over 120 peer reviewed papers in all areas of clinical chemistry and in the last ten years developed a strong collaboration with the Oxford Obstetric team which has led to a series of publications encompassing diagnosis of pre-eclampsia, developing pregnancy specific reference intervals and identifying newer markers of obstetric disease.
Wednesday Nov 8 2023 5 pm (CET)
Soluble HLA (sHLA) peptides are thought to have great potential as biomarkers for different diseases such as cancer. However, efficient enrichment of sHLA peptides from body fluids like plasma has been a bottleneck, requiring 3-5 ml per patient. Here we present IMBAS-MS, an automated magnetic bead based workflow for the efficient enrichment of HLA protein peptide complexes.
The core of IMBAS-MS is the combination of biotinylated antibodies captured by streptavidin magnetic beads allowing for an automated one pot enrichment from only 200 µl plasma.
In combination with Whisper low-flow gradients, data-independent acquisition (DIA) and computational library-based analysis we acquire deep immunopeptidomes from single measurements, elucidating its origins.
Tuesday Oct 31 2023 3 pm (CET)
Our guest speaker for the series will be Stephen MacDonald, CPD assessor and a Principal Clinical Scientist at Cambridge University Hospitals NHS Foundation Trust.
In the first of the three sessions, we will introduce commonly used statistical methods, terms and concepts. Topics will include statistical summaries such as mean, variance, standard deviation and coefficient of variation.
We will draw the distinction between imprecision and bias, and how both contribute to the quality of our results.
We will learn how statistics are used and what other calculations they feed into, including total error and measurement uncertainty. Using practical examples and case studies to illustrate the concepts discussed we can understand how to apply these statistical principles in your daily laboratory operations.
By the end of this session, participants will:
Whether you are a seasoned professional or new to the field, this session will provide valuable insights and practical knowledge that can be immediately applied in your workplace.
About Stephen MacDonald
Stephen MacDonald is a Principal Clinical Scientist in the field of Specialist Hemostasis working at Cambridge University Hospitals NHS Foundation Trust.
Stephen has a keen interest in the statistical assessment of laboratory assay performance and clinical trials. He has focused on determination of uncertainty of measurement in Specialist Hemostasis assays and in developing models to best describe their performance.
This has led Stephen to participating in National Advisory boards for numerous aspects of Laboratory Hemostasis as well as publishing a range of journal articles in The Journal of Laboratory and Precision Medicine and the International Journal of Laboratory Hematology.
Wednesday Oct 18 2023 5 pm (CEST)
Multiple myeloma is a complex form of plasma cell cancer that is currently untreatable. There are approximately 200,000 new diagnoses each year globally, with a 100% relapse rate and 54% five-year overall survival rate. In spite of significant advancements in treating blood-related cancers, these diseases continue to be a substantial cause of illness and death worldwide.
In this webinar, Dr. Todd Druley, MD, Ph.D., Chief Medical Officer of Mission Bio, and Co-Founder and Chief Technology Officer Dr. Adam Sciambi, Ph.D., will:
• Discuss the clinical impact and horizon of multiple myeloma therapies
• Present a novel approach to multiple myeloma therapeutic development by correlating SNVs, CNVs, and surface epitopes for clonal profiling
• Share clinical data generated by researchers from The Cancer Research Center of Toulouse IUCT-Oncopole and Genentech
Tuesday June 13 2023 4 pm (CEST)
Join us at Randox Webinar: Quality Control in Laboratory Diagnostics – Practical Guidance in Troubleshooting.
We will be hosting the second webinar in our series with Dr Mairiead MacLennan on 13th June 2023 at 3PM (BST).
Dr Mairiead MacLennan manages a diagnostic laboratory in the United Kingdom with over over 40 years multidisciplinary experience, focused on Quality and Training and will be discussing her own experiences to provide insight, advice and guidance
The second webinar will focus on:
Dr Mairiead MacLennan is a registered HCPC Biomedical Scientist with over 40 years multidisciplinary diagnostic laboratory experience in both NHS and Veterinary medicine specialising in Quality and Training.
If you cannot attend, please fill out the registration form and we will send you a full recording post webinar!
Thursday Mar 30, 2023 05:00 PM (CEST)
Breast cancer is the most diagnosed cancer in the world. Clinically, receptor status and lymph node involvement are essential to stratify patients in different treatment groups. Moreover, molecular subtyping of breast tumours further assists in providing information about prognosis and treatment response. However, complications such as overtreatment, overdiagnosis and late recurrence are still a reality. Therefore, improvements in personalised medicine for better stratification and tailoring of treatment are a necessity. Since proteins are more closely related to phenotype, and information such as post-translational modifications affect protein activity, the use of proteins as biomarkers is of interest. In label-free mass spectrometry (MS)-based proteomics, different acquisition strategies can be used, namely data dependent acquisition (DDA) and data independent acquisition (DIA). Here, we establish a new semi-automated bead-based workflow for high-throughput processing of clinical samples, and further evaluate different acquisition methods. We then investigate the potential use of proteome data in comparison with already available matched transcriptome data in the context of personalised medicine and biomarker discovery.
Thursday Feb 23, 2023 11:00 AM in Eastern Time (US and Canada)
Genome-wide bulk sequencing is widely used to assess DNA methylation (DNAm). However, methylation signals obtained from bulk sequencing are averaged out, concealing the cell-to-cell differences in methylation signatures involved in health and disease. Single-cell methods such as bisulfite sequencing were developed to reveal these signatures and offer insights into cellular heterogeneity and rare cell types. However, genome-wide DNAm profiling at single-cell resolution has drawbacks such as sparse data and limited genomic coverage even for deeply sequenced samples.
To address this gap, the Renée Beekman Lab and the Lars Velten Lab of the Centre for Genomic Regulation (CRG) in Barcelona teamed up to develop a novel high-throughput, high-confidence targeted bisulfite-free method for analyzing DNAm in single cells, now published in Genome Biology.
In this webinar, authors Michael Scherer, Ph.D. and Agostina Bianchi of CRG will present the Single-Cell Targeted Analysis of the Methylome (scTAM-seq) protocol which profiles 650 biologically relevant CpGs in up to 10,000 cells using the Tapestri platform. They will also share how they combined DNAm (epigenetics), somatic mutations (genotype), and surface marker expression (phenotype) to gain a rich picture of clonal architecture and dynamics across B cell differentiation in blood and bone marrow.
Tuesday, 29th November, 17:00 CET (11:00 EDT)
The EMERGE webinar series is an open platform for emerging researchers to share their work highlighting novel methods and solutions they are implementing to tackle the challenges associated with applying omics technologies in a routine way.
The webinar will focus on two multiomics methodologies that probe the crosstalk between the RNA and the protein worlds, with a specific focus on characterising RNA-protein interactions and RNA and protein subcellular localisation.
OOPS (Orthogonal Organic Phase Separation) repurposes standard Trizol RNA and protein extraction to unbiasedly retrieve all RNA binding proteins and protein bound RNA (Queiroz, Smith & Villanueva, Nature Biotechnology 2019; Villanueva, Smith & Queiroz, Nature Protocols 2020). The unbiased nature of OOPS allows for application across variety of human cells and the first bacterium RNA-binding proteome was retrieved. More recently, LoRNA (Localisation of RNA) was developed, a new single-step subcellular fractionation technology to quantitatively interrogate, at once, the subcellular localisation of the transcriptome, both in organelles and phase separated compartments. Simultaneous interrogation of all localisations allows the system-wide quantification of RNA proportional distribution and the comprehensive analysis of RNA subcellular dynamics. Importantly, by coupling LoRNA and LOPIT (Localisation Of Proteins by Isotope Tagging), a simultaneous system-wide map of the transcriptome and proteome could be obtained. By applying this combined framework to cells undergoing the Unfolded Protein Response the first dynamic map of how the cell co-ordinately reorganises its transcriptome and proteome in stress conditions was generated with unprecedented resolution (Villanueva, Smith & Pizzinga, BioRxiv 2022.
Eneko studied Biology at the Pompeu Fabra University, and later obtained a PhD in Biomedical Research in the University of Barcelona. His research focused on how viruses evolve to optimise their protein synthesis; as well as learning how to engineer them to constrain this synthesis to tumours and develop oncolytic viruses. Currently, as a Welcome Trust Postdoctoral Fellow in the Cambridge Center for Proteomics, he is following the “Keep It Simple” paradigm to develop new technologies combining transcriptomics and proteomics to understand how RNA and proteins interact in space and time.
Thursday Nov 3 11 am CET
Join the Josep Carreras Leukaemia Research Institute (IJC) and Mission Bio for a special in-person symposium where we discuss the tools and treatments shaping the battle to end cancer.
Quantitative characterization of genotype and phenotype at the single-cell level reveals clonal phylogeny and selection at higher resolution, ultimately improving personalized therapeutic selection. By identifying SNVs, CNVs, and surface protein changes and revealing co-occurrence and zygosity of mutations in single cells, Tapestri enables comprehensive insights into disease progression, development of therapy resistance, and MRD.
Our invited speakers will present data from different areas of cancer research like acute myeloid leukemia, chronic lymphocytic leukaemia, myelodysplastic syndrome, acute myeloid leukemia, breast cancer, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
This event is in-person with a virtual attendance option. To register for in-person or virtual attendance and view the full agenda, visit our registration page.
